Microscopic binding of butyrylcholinesterase with quinazolinimine derivatives and the structure–activity correlation

Theoretical Chemistry Accounts (Impact Factor: 2.14). 09/2011; 130(1):69-82. DOI: 10.1007/s00214-011-0965-1

ABSTRACT Butyrylcholinesterase (BChE) is not only an important protein for development of anti-cocaine medication but also an established
drug target to develop new treatment for Alzheimer’s disease (AD). The molecular basis of interaction of a new series of quinazolinimine
derivatives as BChE inhibitors has been studied by molecular docking and molecular dynamics (MD) simulations. The molecular
docking and MD simulations revealed that all of these inhibitors bind with BChE in similar binding mode. Based on the similar
binding mode, we have carried out three-dimensional quantitative structure–activity relationship (3D-QSAR) studies on these
inhibitors using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA),
to understand the structure–activity correlation of this series of inhibitors and to develop predictive models that could
be used in the design of new inhibitors of BChE. The study has resulted in satisfactory 3D-QSAR models. We have also developed
ligand-based 3D-QSAR models. The contour maps obtained from the 3D-QSAR models in combination with the simulated binding structures
help to better interpret the structure–activity relationship and is consistent with available experimental activity data.
The satisfactory 3D-QSAR models strongly suggest that the determined BChE-inhibitor binding modes are reasonable. The identified
binding modes and developed 3D-QSAR models for these BChE inhibitors are expected to be valuable for rational design of new
BChE inhibitors that may be valuable in the treatment of Alzheimer’s disease.

KeywordsButyrylcholinesterase–Inhibitor–Binding mode–Modeling

  • [Show abstract] [Hide abstract]
    ABSTRACT: Insufficient cholinergic neurotransmission in AD is responsible for a progressive loss of cognition and motor capacities. The cholinergic hypothesis has provided the rationale for the current treatment approaches based on acetylcholinesterase inhibitors. However, recent data focus on the complex nature of AD and disclose the involvement of other neurotransmitters such as serotonin, noradrenalin, dopamine, histamine, excitatory amino acids and neuropeptides among others. Interestingly, recent research has revealed that in severe AD brains the levels of AChE are considerably reduced whereas BuChE activity increases, thus aggravating the toxicity of beta A. In such instances, it is possible that BuChE may be a more suitable target than AChE. Oxidative stress has been implicated in CNS degenerative disorders such as AD and PD. Therefore, owing to their capacity to inhibit oxidative damage, MAOIs are potential candidates as anti-Alzheimer drugs. More recently, a novel drug--TV3326--was designed, based upon two pharmacophores: the carbamate moiety from rivastigmine, an AChE inhibitor; and the propargyl group from rasagiline, a MAO inhibitor. This drug exhibits cholinesterase and selective brain MAO inhibitory activities, reduces apoptosis and stimulates the processing of APP alpha, hence reducing the possibility of generation of the toxic beta A. Thus, TV3326 may be expected to contribute positively to the cognitive benefits of Alzheimer's patients. Anyhow, the development of drugs with several targets and diverse pharmacological properties may conclusively demonstrate the most beneficial therapy.
    Current Pharmaceutical Design 02/2004; 10(25):3167-75. · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a chronic, progressive, neurodegenerative disorder that places a substantial burden on patients, their families, and society. The disease affects approximately 5 million individuals in the United States, with an annual cost of care greater than $100 billion. During the past dozen years, several agents have been approved that enhance cognition and global function of AD patients, and recent advances in understanding AD pathogenesis has led to the development of numerous compounds that might modify the disease process. A wide array of antiamyloid and neuroprotective therapeutic approaches are under investigation on the basis of the hypothesis that amyloid beta (A beta) protein plays a pivotal role in disease onset and progression and that secondary consequences of A beta generation and deposition, including tau hyperphosphorylation and neurofibrillary tangle formation, oxidation, inflammation, and excitotoxicity, contribute to the disease process. Interventions in these processes with agents that reduce amyloid production, limit aggregation, or increase removal might block the cascade of events comprising AD pathogenesis. Reducing tau hyperphosphorylation, limiting oxidation and excitotoxicity, and controlling inflammation might be beneficial disease-modifying strategies. Potentially neuroprotective and restorative treatments such as neurotrophins, neurotrophic factor enhancers, and stem cell-related approaches are also under investigation.
    Alzheimer's & dementia: the journal of the Alzheimer's Association 03/2008; 4(2):65-79. · 14.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The coupling of two different pharmacophores, each endowed with different biological properties, afforded the hybrid compound lipocrine (7), whose biological profile was markedly improved relative to those of prototypes tacrine and lipoic acid. Lipocrine is the first compound that inhibits the catalytic activity of AChE and AChE-induced amyloid-beta aggregation and protects against reactive oxygen species. Thus, it emerged as a valuable pharmacological tool to investigate Alzheimer's disease and as a promising lead compound for new anti-Alzheimer drugs.
    Journal of Medicinal Chemistry 02/2005; 48(2):360-3. · 5.48 Impact Factor